Department of Pediatrics, Zhongnan Hospital of Wuhan University, Wuhan - China.
Department of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan - China.
Arq Bras Cardiol. 2021 Nov;117(5):911-921. doi: 10.36660/abc.20200733.
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide.
To investigate the association between hypertension and severity/mortality in hospitalized patients with COVID-19 in Wuhan, China.
A total of 337 patients diagnosed with COVID-19 at the Seventh Hospital of Wuhan City, from January 20 to February 25, 2020, were enrolled and analyzed in a retrospective, single-center case study. The significance level adopted in the statistical analysis was 0.05.
Of the 337 patients with confirmed diagnosis of COVID-19, 297 (87.8%) were discharged from the hospital and 40 patients (22.9%) died. The median age was 58 years (range, 18-91 years). There were 112 (33.2%) patients diagnosed with hypertension at admission (median age, 65.0 years [range, 38-91 years]; 67 [59.8%, 95%CI: 50.6%-69.0%] men, p=0.0209). Patients with hypertension presented a significantly higher portion of severe cases (69 [61.6%, 95%CI:52.5%-70.8%] vs. 117 [52.0%, 95%CI: 45.4%-58.6%] in severe patients and 23 [19.3%, 95%CI:12.9%-28.1%] vs. 27 [12.0%, 95%CI: 7.7%-16.3%] in critical patients, p=0.0014) and higher mortality rates (20 [17.9%, 95%CI: 10.7%-25.1%] vs. 20 [8.9%, 95%CI: 5.1%-12.6%, p=0.0202). Moreover, hypertensive patients presented abnormal levels of multiple indicators, such as lymphopenia, inflammation, heart, liver, kidney, and lung function at admission. The hypertension group still displayed higher levels of TnT and creatinine at approaching discharge.
Hypertension is strongly associated with severity or mortality of COVID-19. Aggressive treatment may be considered for COVID-19 patients with hypertension, especially regarding cardiac and kidney injury.
由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)已在全球范围内传播。
调查中国武汉市住院 COVID-19 患者中高血压与严重程度/死亡率之间的关系。
采用回顾性、单中心病例研究方法,纳入 2020 年 1 月 20 日至 2 月 25 日期间武汉市第七医院确诊的 337 例 COVID-19 患者。统计分析的显著性水平为 0.05。
337 例确诊 COVID-19 的患者中,297 例(87.8%)出院,40 例(22.9%)死亡。中位年龄为 58 岁(范围 18-91 岁)。入院时诊断为高血压的患者有 112 例(33.2%)(中位年龄 65.0 岁[范围 38-91 岁];67 例[59.8%,95%CI:50.6%-69.0%]为男性,p=0.0209)。高血压患者中严重病例的比例明显更高(69[61.6%,95%CI:52.5%-70.8%] vs. 117[52.0%,95%CI:45.4%-58.6%]为严重病例,23[19.3%,95%CI:12.9%-28.1%] vs. 27[12.0%,95%CI:7.7%-16.3%]为危急病例,p=0.0014),死亡率也更高(20[17.9%,95%CI:10.7%-25.1%] vs. 20[8.9%,95%CI:5.1%-12.6%],p=0.0202)。此外,高血压患者入院时多个指标(如淋巴细胞减少、炎症、心、肝、肾和肺功能)异常,在接近出院时,高血压组的 TnT 和肌酐水平仍较高。
高血压与 COVID-19 的严重程度或死亡率密切相关。对于 COVID-19 合并高血压的患者,可能需要积极治疗,特别是关注心脏和肾脏损伤。